La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Bod Science Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jo Patterson

Amministratore delegato

AU$524.5k

Compenso totale

Percentuale dello stipendio del CEO	71.1%
Mandato del CEO	6.5yrs
Proprietà del CEO	4.0%
Durata media del management	2.5yrs
Durata media del Consiglio di amministrazione	5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jo Patterson rispetto agli utili di Bod Science?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2023	AU$524k	AU$373k	-AU$8m
Mar 31 2023	n/a	n/a	-AU$7m
Dec 31 2022	n/a	n/a	-AU$6m
Sep 30 2022	n/a	n/a	-AU$6m
Jun 30 2022	AU$520k	AU$341k	-AU$5m
Mar 31 2022	n/a	n/a	-AU$5m
Dec 31 2021	n/a	n/a	-AU$5m
Sep 30 2021	n/a	n/a	-AU$5m
Jun 30 2021	AU$557k	AU$331k	-AU$4m
Mar 31 2021	n/a	n/a	-AU$4m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$5m
Jun 30 2020	AU$421k	AU$315k	-AU$5m
Mar 31 2020	n/a	n/a	-AU$6m
Dec 31 2019	n/a	n/a	-AU$6m
Sep 30 2019	n/a	n/a	-AU$7m
Jun 30 2019	AU$339k	AU$300k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$6m
Dec 31 2018	n/a	n/a	-AU$5m
Sep 30 2018	n/a	n/a	-AU$4m
Jun 30 2018	AU$294k	AU$250k	-AU$4m
Mar 31 2018	n/a	n/a	-AU$3m
Dec 31 2017	n/a	n/a	-AU$3m
Sep 30 2017	n/a	n/a	-AU$3m
Jun 30 2017	AU$344k	AU$250k	-AU$3m

Compensazione vs Mercato: La retribuzione totale di Jo ($USD 343.82K ) è circa la media per le aziende di dimensioni simili nel mercato Australian ($USD 299.11K ).

Compensazione vs guadagni: La retribuzione di Jo è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Jo Patterson

6.5yrs

Mandato

AU$524,465

Compensazione

Ms. Joanne Patterson, also known as Jo, MBus. (Marketing), serves as Chief Executive Officer of Bod Science Limited (formerly known as Bod Australia Limited). Ms. Patterson founded Bod Australia in 2014.M...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Joanne Patterson	CEO, Executive Director & Member of Medical Advisory Board	no data	AU$524.47k	4.05% A$ 172.2k
Adrian Sturrock	Chief Financial Officer	2.5yrs	AU$414.34k	0.11% A$ 4.8k
Craig Weller	CTO & Member of Medical Advisory Board	no data	AU$432.81k	2.74% A$ 116.5k
Adele Hosseini	Chief Scientific Officer & Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
Alan Dworkin	Advisor	2.5yrs	Nessun dato	Nessun dato
Carlie Hodges	Company Secretary	1.1yrs	Nessun dato	Nessun dato

2.5yrs

Durata media

Gestione esperta: Il team dirigenziale di BOD è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Joanne Patterson	CEO, Executive Director & Member of Medical Advisory Board	6.5yrs	AU$524.47k	4.05% A$ 172.2k
Craig Weller	CTO & Member of Medical Advisory Board	6.5yrs	AU$432.81k	2.74% A$ 116.5k
Adele Hosseini	Chief Scientific Officer & Member of Medical Advisory Board	6.5yrs	Nessun dato	Nessun dato
David Baker	Non-Executive Chairman	1.8yrs	AU$89.37k	3.59% A$ 153.0k
Ian Olver	Member of Medical Advisory Board	3.2yrs	Nessun dato	Nessun dato
George Livery	Non-Executive Director	5.4yrs	AU$66.19k	0.22% A$ 9.5k
Stella Valenzuela	Member of Medical Advisory Board	6.5yrs	Nessun dato	Nessun dato
Nick Burgess	Member of Medical Advisory Board	6.5yrs	Nessun dato	Nessun dato
Akash Bedi	Non-Executive Director	4.6yrs	AU$66.19k	Nessun dato
Iain McGregor	Member of Medical Advisory Board	3.2yrs	Nessun dato	Nessun dato
Arman Sabet	Member of Medical Advisory Board	3.2yrs	Nessun dato	Nessun dato
Andrew McLachlan	Member of Medical Advisory Board	3.2yrs	Nessun dato	Nessun dato

5.0yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BOD sono considerati esperti (durata media dell'incarico 5 anni).

Bod Science Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Bod Science Limited Announces Company Secretary Changes

Less than half of directors are independent

Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive Director

Bod Australia Limited, Annual General Meeting, Nov 28, 2022

Bod Australia Limited Announces Board Changes

Recent updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)

Bod Science Limited Announces Company Secretary Changes

Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) Study

Less than half of directors are independent

Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive Director

Bod Australia Limited, Annual General Meeting, Nov 28, 2022

Full year 2022 earnings released: AU$0.051 loss per share (vs AU$0.043 loss in FY 2021)

Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in July

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Announces Board Changes

Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical Trial

Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal Cannabis

Less than half of directors are independent

Bod Australia Announces Board Changes

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Bod Australia Limited's Novel Food Application Accepted by UK Food Service Agency

Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical Trial

Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency

Here's Why We're Watching Bod Australia's (ASX:BDA) Cash Burn Situation

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)

Bod Australia Limited Launches New CBD -Based Products

Bod Australia (ASX:BDA) Is In A Good Position To Deliver On Growth Plans

Bod Australia Limited Provides Update on New Medicinal Cannabis Product Launch

Chief Financial Officer has left the company

Why Bod Australia's (ASX:BDA) CEO Pay Matters

Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021

New 90-day low: AU$0.42

Bod Australia Limited announced that it expects to receive AUD 8 million in funding

Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global Partner

New 90-day high: AU$0.61

Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales Continues

Bod Australia Limited Launches CBD Products in the Netherlands

Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple Formulations

New 90-day high: AU$0.53

New 90-day high: AU$0.40

New 90-day high - AU$0.30

Earnings released

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media